Cara Therapeutics Inc (NAS:CARA)
$ 0.378 -0.0719 (-15.98%) Market Cap: 20.73 Mil Enterprise Value: -13.94 Mil PE Ratio: 0 PB Ratio: 37.80 GF Score: 35/100

Cara Therapeutics Inc to Discuss the US License Agreement for I.V. Korsuva with Vifor Pharma PLC Call Transcript

Oct 20, 2020 / 12:30PM GMT
Release Date Price: $14.86 (+6.68%)
Operator

Good morning and welcome to Cara Therapeutics/Vifor Pharma License Conference Call. (Operator Instructions)

Please be advised that this call is being recorded by Cara's request.

I would now like to turn the call over to the Cara team. Please proceed.

Jack Hildick;Smith
Stern Investor Relations, Inc. - Analyst

Good morning. This is Jack Hildick-Smith with Stern Investor Relations and welcome to Cara Therapeutics/Vifor Pharma License Update Conference Call.

The news release describing the details of this license agreement became available at 1 a.m. today and can be found on our website at www.caratherapeutics.com, with further details available in a current report on Form 8-K filed with the U.S. Securities and Exchange Commission this morning. A PowerPoint slide deck describing the details of the Vifor license is posted on the Investors section of the website, and you may also listen to a live webcast and replay of today's call on the same

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot